^
Association details:
| Biomarker: | NRP1 elevation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
Excerpt:
Patients with low baseline expression of neuropilin-1 also showed a trend toward improved overall survival (HR, 0.75; 95% CI, 0.59 to 0.97) versus patients with high neuropilin-1 expression (HR, 1.07; 95% CI, 0.81 to 1.40; interaction P = .06).
Secondary therapy:
cisplatin + capecitabine; cisplatin + 5-fluorouracil
DOI:
10.1200/JCO.2011.39.9824